Security Snapshot

VERVE THERAPEUTICS INC - COMMON STOCK Institutional Ownership

CUSIP: 92539P101

13F Institutional Holders and Ownership History from Q4 2023 to Q3 2024

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / COMMON STOCK
Shares outstanding
85,151,237
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • 92539P101 - VERVE THERAPEUTICS INC - COMMON STOCK is tracked under CUSIP 92539P101.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 1 between Q2 2024 and Q3 2024.
  • Reported value moved from $48,650,730 to $20,585,570.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 92539P101?
CUSIP 92539P101 identifies 92539P101 - VERVE THERAPEUTICS INC - COMMON STOCK in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of VERVE THERAPEUTICS INC - COMMON STOCK based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 3.8% 3,235,747 STATE STREET CORPORATION 31 Dec 2024

Institutional Holders of VERVE THERAPEUTICS INC - COMMON STOCK across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q3 4,253,217 $20,585,570 +$4,374,435 $4.84 1
2024 Q2 9,969,412 $48,650,730 -$2,445,724 $4.88 2
2024 Q1 10,470,585 $139,049,369 +$28,795,555 $13.28 2
2023 Q4 8,302,245 $115,733,296 $13.94 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .